Rather, CB-839 suppresses tumor growth by reducing intracellular glutamate stores required for TCA cycle anaplerosis (36, 53) and amino acid synthesis—a suppression reversible by either glutamate supplementation or blocking glutamate export through the transporter xCT using erastin (36). The gene discussed is SLC7A11; the disease is neoplasm.